Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Healthy

Interventions

DRUG

Adalimumab (BCD-057)

Adalimumab is a monoclonal antibody against tumor necrosis factor alpha

DRUG

Adalimumab (Humira)

Adalimumab is a monoclonal antibody against tumor necrosis factor alpha

Trial Locations (1)

LLC BioEk, Saint Petersburg